Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice

Overview

Journal J Crohns Colitis

Publisher Oxford University Press

Date 2015 Dec 19

PMID 26681763

Citations 44

Authors

Emily E Vivio

Navya Kanuri

Joanna J Gilbertsen

Kelly Monroe

Neelendu Dey

Chien-Huan Chen

Alexandra M Gutierrez

Matthew A Ciorba

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Vedolizumab inhibits leucocyte vascular adhesion and migration into the gastrointestinal tract through α4β7 integrin blockade. This agent became available in mid-2014 for the treatment of moderate to severe Crohn's disease (CD) and UC (UC). The aim of this study was to assess the patterns of use, effectiveness and safety of vedolizumab in an inflammatory bowel disease (IBD) clinical practice.

Methods: Patients beginning vedolizumab were enrolled with informed consent. A prospective cohort was followed with laboratory, disease activity and quality-of-life assessments made during infusion visits up to week 14. Duration of vedolizumab use, mucosal healing and safety were analysed retrospectively for all patients not captured in the prospective component of this study.

Results: One hundred and two patients started vedolizumab, with 51 patients (30 CD, 21 UC) followed prospectively. The CD patients exhibited a significant decrease in Crohn's Disease Activity Index (p = 0.04) and Harvey-Bradshaw index (p < 0.01) by week 14. The UC patients demonstrated improved partial Mayo scores at weeks 6 (p < 0.01) and 14 (p < 0.001). Ninety percent of all CD and UC patients remained on vedolizumab up to week 14. IBD-related quality of life was improved by week 6 in CD and UC cohorts (p = 0.02 and p < 0.01 respectively). Colectomy for lack of response and systemic histoplamosis were notable reasons for early discontinuation of vedolizumab, which was otherwise well tolerated.

Conclusions: Vedolizumab was efficacious and a high percentage of patients continued this therapy beyond induction dosing. Observed safety signals may be attributed to the refractory IBD disease state of this early-adopting clinical cohort.

Citing Articles

Treat to target in Crohn's disease: A practical guide for clinicians.

Srinivasan A World J Gastroenterol. 2024; 30(1):50-69.

PMID: 38293329 PMC: 10823901. DOI: 10.3748/wjg.v30.i1.50.

Impact of Vedolizumab on Extraintestinal Manifestations in Inflammatory Bowel Disease: Results From a Descriptive, Retrospective, Real-world Study.

Kopylov U, Burisch J, Ben-Horin S, Braegger F, Fernandez-Nistal A, Lara N Inflamm Bowel Dis. 2023; 29(11):1713-1722.

PMID: 37158585 PMC: 10628928. DOI: 10.1093/ibd/izad075.

Can we change the natural course of inflammatory bowel disease?.

Le Berre C, Danese S, Peyrin-Biroulet L Therap Adv Gastroenterol. 2023; 16:17562848231163118.

PMID: 37153497 PMC: 10159495. DOI: 10.1177/17562848231163118.

Post-inflammatory Abdominal Pain in Patients with Inflammatory Bowel Disease During Remission: A Comprehensive Review.

Takahashi K, Khwaja I, Schreyer J, Bulmer D, Peiris M, Terai S Crohns Colitis 360. 2023; 3(4):otab073.

PMID: 36777266 PMC: 9802269. DOI: 10.1093/crocol/otab073.

Vedolizumab Experience in Children and Adolescents With Inflammatory Bowel Disease: A Multicenter Observational Study.

Hajjat T, Mosha M, Whaley K, Rosen M, Suppa C, Markowitz J Crohns Colitis 360. 2023; 3(3):otab039.

PMID: 36776669 PMC: 9802305. DOI: 10.1093/crocol/otab039.

References

Bryant R, Sandborn W, Travis S . Introducing vedolizumab to clinical practice: who, when, and how?. J Crohns Colitis. 2015; 9(4):356-66. DOI: 10.1093/ecco-jcc/jjv033. View

Silverberg M, Satsangi J, Ahmad T, Arnott I, Bernstein C, Brant S . Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 Suppl A:5A-36A. DOI: 10.1155/2005/269076. View

Lewis J, Chuai S, Nessel L, Lichtenstein G, Aberra F, Ellenberg J . Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008; 14(12):1660-6. PMC: 2597552. DOI: 10.1002/ibd.20520. View

Chen C, Kularatna G, Stone C, Gutierrez A, Dassopoulos T . Clinical experience of natalizumab in Crohn's disease patients in a restricted distribution program. Ann Gastroenterol. 2014; 26(3):189-190. View

Feagan B, Rutgeerts P, Sands B, Hanauer S, Colombel J, Sandborn W . Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369(8):699-710. DOI: 10.1056/NEJMoa1215734. View

Hagan M, Cross R . Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis. Expert Opin Drug Saf. 2015; 14(9):1473-9. DOI: 10.1517/14740338.2015.1063612. View

Ha C, Ullman T, Siegel C, Kornbluth A . Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol. 2012; 10(9):1002-7. DOI: 10.1016/j.cgh.2012.02.004. View

Irvine E, Zhou Q, Thompson A . The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol. 1996; 91(8):1571-8. View

Best W, Becktel J, SINGLETON J, KERN Jr F . Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70(3):439-44. View

10.

Schroeder K, Tremaine W, Ilstrup D . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317(26):1625-9. DOI: 10.1056/NEJM198712243172603. View

11.

Danese S, Vuitton L, Peyrin-Biroulet L . Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015; 12(9):537-45. DOI: 10.1038/nrgastro.2015.135. View

12.

Sands B, Feagan B, Rutgeerts P, Colombel J, Sandborn W, Sy R . Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014; 147(3):618-627.e3. DOI: 10.1053/j.gastro.2014.05.008. View

13.

Shelton E, Allegretti J, Stevens B, Lucci M, Khalili H, Nguyen D . Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. Inflamm Bowel Dis. 2015; 21(12):2879-85. PMC: 4745906. DOI: 10.1097/MIB.0000000000000561. View

14.

Daperno M, DHaens G, Van Assche G, Baert F, Bulois P, Maunoury V . Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004; 60(4):505-12. DOI: 10.1016/s0016-5107(04)01878-4. View

15.

Targan S, Feagan B, Fedorak R, Lashner B, Panaccione R, Present D . Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007; 132(5):1672-83. DOI: 10.1053/j.gastro.2007.03.024. View

16.

Iskandar H, Ciorba M . Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res. 2012; 159(4):313-25. PMC: 3308116. DOI: 10.1016/j.trsl.2012.01.001. View

17.

Sandborn W, Feagan B, Rutgeerts P, Hanauer S, Colombel J, Sands B . Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013; 369(8):711-21. DOI: 10.1056/NEJMoa1215739. View

18.

Harvey R, Bradshaw J . A simple index of Crohn's-disease activity. Lancet. 1980; 1(8167):514. DOI: 10.1016/s0140-6736(80)92767-1. View

19.

Juillerat P, Wasan S, Fowler S, Friedman S, Pabby V, Coukas J . Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals. Inflamm Bowel Dis. 2013; 19(11):2457-63. DOI: 10.1097/MIB.0b013e3182a32a0d. View

20.

Sakuraba A, Keyashian K, Correia C, Melek J, Cohen R, Hanauer S . Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013; 19(3):621-6. PMC: 4779049. DOI: 10.1097/MIB.0b013e31827eea78. View